Vir Biotechnology, Inc. · NASDAQ:VIR
Vir Biotechnology — 43rd Annual J.P. Morgan Healthcare Conference 2025
18 slides from Vir Biotechnology's conference presentation, Jan 14, 2025
Slide 1: J.P. Morgan 2025 Healthcare Conference
J.P. Morgan 2025 Healthcare Conference January 14, 2025 Confidential © 2024 Vir Biotechnology, Inc. 1
Slide 2: Legal disclaimer
Legal disclaimer Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: the therapeutic potential of Vir Biotechnology's oncology solid tu
Slide 3: Our Vision: Powering The Immune System To Transform Lives
Our Vision: Powering The Immune System To Transform Lives 2025 Vir Biotechnology, Inc. 3
Slide 4: We power the immune system to fight back against cancer and viruses
We power the immune system to fight back against two related and formidable threats: cancer and viruses Protecting us from cancer cells and Cancer cells and viruses can evade the We power the immune system to fight viruses in normal conditions immune system, causing serious back against cancer and i
Slide 5: Resulting in 5 clinical programs across oncology and infectious disease
Resulting in 5 clinical programs across oncology and infectious disease Leveraging Immune-Targeted Approaches to Transform Patient Care Oncology – Solid Tumors Infectious Disease HER2 PSMA EGFR Hepatitis Delta Chronic Hepatitis B (Phase 1) (Phase 1) (Initiating Phase 1) (Initiating Phase 3) (Phase 2
Slide 6: PRO-XTEN masked TCEs have potential best-in-class therapeutic index and durability
In oncology, PRO-XTENTM masked TCEs have potential PRO-XTEN best-in-class therapeutic index and long-term durability Platform Addressing the challenges of Goal: achieve long-term, Proteases in the TME unmasked and single-masked durable responses to a broad selectively cleave linkers set of solid tum
Slide 7: Dramatic patient responses with PRO-XTEN masked TCEs in Phase 1
We have already seen dramatic patient responses VIR-5818 with PRO-XTENTM masked TCEs in Phase 1 trials (HER2) Tumor pain, inflammation Day 1 Baseline Cycle 1 Day 8 Cycle 2 Day 1 VIR-5818 (HER2) Phase 1 Case Study Compelling activity in breast cancer patient by Cycle 1 (dose up to 1000 µg/kg) 9 prior
Slide 8: VIR-5818 deep responses at early doses in mCRC and other HER2 tumors
For VIR-5818, we see deep responses at early doses in VIR-5818 mCRC and other HER2 tumors (HER2) HER2+ Colorectal Cancer Dose Levels (All Patients Shown are MSS) Early Phase 1 efficacy: 100-300 µg/kg 400 µg/kg 600 µg/kg Activity HER2+ CRC ≥400 µg/kg 800 µg/kg cPR 2/6 (33%) 1000 µg/kg CEA Case * CEA
Slide 9: VIR-5500 shows strong PSA50 responses and tolerable safety at early doses
With VIR-5500, our phase 1 data show strong PSA50 VIR-5500 responses and tolerable safety at early doses (PSMA) PSA Responses (1st dose ≥ 120 ug/kg) 120/180/180 μg/kg QW Early Phase 1 responses: 25 120/180/180 μg/kg QW 200/300/400 μg/kg QW from Baseline 25 200/300/400 μg/kg QW PSA Best % Change from
Slide 10: PRO-XTEN masked TCEs can expand the potential of T-cell engagers
PRO-XTENTM masked TCEs can expand the potential of PRO-XTEN Platform T-cell engagers in cancer treatment PRO-XTENTM Masked TCEs VIR-5818 (HER2xCD3): The only masked HER2-targeted TCE, significant room to dose escalate including Q3W dosing • Efficacy: 33% response and 100% biomarker response in mCRC,
Slide 11: Hepatitis Delta dramatically increases risk of death, cirrhosis, and cancer
In infectious disease, we target Hepatitis Delta, which HDV dramatically increases risk of death, cirrhosis, and cancer >50% Liver-Related Death in 10 Years1 ~100,000 US Patients4 5 year Average Progression to Cirrhosis and Liver Failure2 ~200,000 EU Patients4 Risk of Liver Cancer 3x (HCC) vs. HBV3
Slide 12: Tobevibart + elebsiran shows transformative HDV virological responses
Tobevibart + elebsiran combo has shown transformative HDV virological responses in HDV in our ongoing P2 trial Virologic Endpoint: Tobevibart (mAb) + elebsiran (siRNA) combination therapy HDV RNA <Target Not Detected (0 IU/mL)* Key differentiators 100% P2: SOLSTICE 100% P3: MYR 301 1 Deep HDV antivi
Slide 13: ECLIPSE registrational clinical trials begin in H1 2025
We aim to establish a new standard of care in HDV, and HDV ECLIPSE registrational clinical trials begin in H1 2025 Supported by: ✓ FDA breakthrough designation ✓ FDA Fast Track ✓ EMA PRIME designation ✓ EMA ODD ECLIPSE 1 – Phase 3 HDV RNA LLOQ, TND + ALT normalization at week 48 tobevibart + elebsir
Slide 14: Clinical development underpinned by financial discipline, runway into mid-2027
Clinical development is underpinned by strict financial discipline, enabling runway into mid-2027 Financial Highlights Accelerate and Invest Partnership Programs Cash runway into Hepatitis Delta Hepatitis B mid-2027 Functional cure data Q2’25 Phase 3 starts H1’25 Masked TCEs Further advancement is ~
Slide 15: Multiple assets in oncology and infectious disease positioned for near-term value creation
With multiple assets in oncology and infectious disease, we are well positioned for near-term value creation siRNA Antibody Masked TCE Disease Area Product Candidate Goal Pre-clinical Phase 1 Phase 2 Phase 3 Approval Partner Accelerate and Invest Chronic Alnylam tobevibart ± elebsiran Treatment Hepa
Slide 16: We anticipate multiple important near-term program catalysts
We anticipate multiple important near-term program catalysts Program Drug Candidates/Regimen Catalyst Timing VIR-5818: dual-masked HER2xCD3 TCE Solid Tumors VIR-5500: dual-masked PSMAxCD3 TCE Phase 1: initial monotherapy data Jan. 8th Hepatitis Delta tobevibart (mAb) + elebsiran (siRNA) ECLIPSE: reg
Slide 17: Vir Biotechnology: powering the immune system to transform lives
Vir Biotechnology: powering the immune system to transform lives Delivering on promise of universal dual-masked TCEs in cancer treatment Clinical proof of concept for PRO-XTEN platform Transformative virological responses in HDV Phase 3 start in H1 2025 $1.1 billion cash and investments1 (January 20
Slide 18: Patients Are Waiting
PATIENTS ARE WAITING © 2023 PROPERTY OF VIR BIOTECHNOLOGY, INC. 18 2025 Vir Biotechnology, Inc. 18
Vir Biotechnology — 43rd Annual J.P. Morgan Healthcare Conference 2025 on 6ix